Skip Navigation


NDT Advance Access originally published online on September 27, 2006
Nephrology Dialysis Transplantation 2007 22(2):552-559; doi:10.1093/ndt/gfl559
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/2/552    most recent
gfl559v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Szeto, C.-C.
Right arrow Articles by Li, P. K.-T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szeto, C.-C.
Right arrow Articles by Li, P. K.-T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products—A 1-year randomized control trial

Cheuk-Chun Szeto1, Kai-Ming Chow1, Christopher Wai-Kei Lam2, Chi-Bon Leung1, Bonnie Ching-Ha Kwan1, Kwok-Yi Chung1, Man-Ching Law1 and Philip Kam-Tao Li1

1Department of Medicine & Therapeutics and 2Department of Chemical Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China

Correspondence and offprint requests to: Dr C.-C. Szeto, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China. Email: ccszeto{at}cuhk.edu.hk



  Abstract

Background. Chronic utilization of a bio-incompatible peritoneal dialysis (PD) solution with acidic pH and a high content of glucose degradation product (GDP) has been implicated as a contributing cause of peritoneal failure. We compared a newly formulated solution of neutral pH and low levels of GDP to a standard PD solution.

Methods. Fifty new PD patients were randomized to a conventional lactate-buffered fluid (control) and a pH neutral, lactate-buffered, low GDP solution (balance). Patients were followed for 12 months. Serum samples were assayed for C-reactive protein (CRP). PD effluent was collected and assayed for cancer antigen-125 (CA125) and hyaluronan (HA). Clinical end points were the residual renal function and dialysis adequacy indices.

Results. After 52 weeks of treatment, PD fluid CA125 rose from 2.45 ± 0.96 to 14.30 ± 2.17 U/ml (P < 0.001), and HA declined from 2.26 ± 0.60 to 1.45 ± 0.32 µg/ml (P = 0.07) in the balance group. The balance group had a higher PD fluid CA-125 (14.30 ± 2.17 vs 7.36 ± 2.23 U/ml, P = 0.007), lower HA (1.45 ± 0.32 vs 2.55 ± 0.32 µg/ml, P = 0.007), and lower serum CRP level (1.77 ± 0.42 vs 7.73 ± 2.42 mg/l, P = 0.026) than the control group at 52 weeks. There was no difference in dialysis adequacy indices, ultrafiltration volume, urine output, residual renal function, peritonitis rate or need of hospitalization in 1 year.

Conclusion. As compared to conventional PD solution, the use of balance, a neutral pH, low GDP solution resulted in a superior profile of PDE mesothelial cell marker and a lower degree of systemic inflammation, and the difference was maintained for 1 year. It remains to be determined whether these effects could result in better long-term clinical outcome.

Keywords: biocompatibility; inflammation; nutrition; renal failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 pdiHome page
S. L.S. Fan
SHOULD WE USE BIOCOMPATIBLE PD SOLUTIONS FOR ALL PATIENTS?
Perit. Dial. Int., November 1, 2009; 29(6): 630 - 633.
[Full Text] [PDF]

Home page
 pdiHome page
M. Rumpsfeld, S. P. McDonald, and D. W. Johnson
PERITONEAL SMALL SOLUTE CLEARANCE IS NONLINEARLY RELATED TO PATIENT SURVIVAL IN THE AUSTRALIAN AND NEW ZEALAND PERITONEAL DIALYSIS PATIENT POPULATIONS
Perit. Dial. Int., November 1, 2009; 29(6): 637 - 646.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
L. Weiss, B. Stegmayr, G. Malmsten, M. Tejde, H. Hadimeri, C. E. Siegert, J. Ahlmen, R. Larsson, B. Ingman, O. Simonsen, et al.
BIOCOMPATIBILITY AND TOLERABILITY OF A PURELY BICARBONATE-BUFFERED PERITONEAL DIALYSIS SOLUTION
Perit. Dial. Int., November 1, 2009; 29(6): 647 - 655.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Kim, J. Oh, S. Kim, W. Chung, C. Ahn, S. G. Kim, and K.-H. Oh
Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2899 - 2908.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. J. Davies
Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?
Nephrol. Dial. Transplant., September 1, 2009; 24(9): 2620 - 2622.
[Full Text] [PDF]

Home page
 pdiHome page
R. T. Krediet
BIOCOMPATIBILITY AND PERITONEAL TRANSPORT
Perit. Dial. Int., March 1, 2009; 29(2): 147 - 149.
[Full Text] [PDF]

Home page
 pdiHome page
V. La Milia, M. Limardo, M. Crepaldi, and F. Locatelli
EFFECTS OF IONIZED SODIUM CONCENTRATIONS ON ULTRAFILTRATION RATE IN PERITONEAL DIALYSIS USING LACTATE AND LACTATE/BICARBONATE SOLUTIONS
Perit. Dial. Int., March 1, 2009; 29(2): 158 - 162.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
P. Tam
PERITONEAL DIALYSIS AND PRESERVATION OF RESIDUAL RENAL FUNCTION
Perit. Dial. Int., February 1, 2009; 29(Supplement_2): S108 - S110.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. G. Blake
Randomized controlled trials in PD
Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2746 - 2748.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.